You are here
By Jack Cush, MD | 06 May 2016
Highlights from this week on RheumNow.com include:
- Registry study (ARTIS & DANBIO) of Spondyloarthritis & Psoriatic arthritis patients show NO cancer risk associated with SpA or PsA; moreover TNF inhibitor use does not augment the cancer risk in these patients.
- May is lupus awareness month.
- CARDERA-2 clinical trial of 154 early RA pts showed that Anakinra+MTX was not better than MTX alone- in early RA - both Xray & clinical outcomes. Questions the value of anakinra in RA.
- Health Canada approves secukinumab for use in psoriatic arthritis and anklylosing spondylitis
- Acute scrotal swelling in Henoch Schonlein purpura occurs in 10-30% of boys, 60% are unilateral. Treatment with steroids?
- Late onset SLE (>50yrs) patients have less cutaneous disease (malar rash, photosensitivity, livedo) but more Sicca Sx
- Metanalysis: TNF inhibitors are shown to be associated with an increase risk of perioperative infections (SSI): BUT the infection risk decreases >38% with temporary cessation of TNFi before surgery.
- Dr. Nicola Dalbeths #Gout review in Lancet is stellar! She's leading the field w/ DECT scans, research & smart Rx.
- RheumNow posts a free download – Patient Guide to Biologics
- FDA REMS/Safety Panel Backs Educational Requirements for Opioid Prescribers
- Simple Referral Rule May Lead to Earlier Referral and Diagnosis of Axial Spondyloarthritis. Rule: needs to 2 of 4 to refer suspected SpA – 1) inflammatory low back pain; 2) back pain > 5 yrs.; 3) good response to NSAIDs; and 4) family history of spondyloarthritis.
- CDC Updates Arthritis Numbers – 25% of US adults have arthritis.
- Poor Outcomes for Dermato/Polymyositis Admitted to ICU.
- Can Rituximab Change the Course of Interstitial Lung Disease.